Connor, Clark & Lunn Investment Management Ltd. Castle Biosciences Inc Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.8 Billion
- Q1 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 77,657 shares of CSTL stock, worth $1.69 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
77,657
Previous 88,570
12.32%
Holding current value
$1.69 Million
Previous $1.91 Million
9.99%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding CSTL
# of Institutions
162Shares Held
25.3MCall Options Held
82.2KPut Options Held
150K-
Black Rock Inc. New York, NY2.6MShares$56.5 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT2.55MShares$55.5 Million0.3% of portfolio
-
Granahan Investment Management, LLC Waltham, MA1.63MShares$35.4 Million1.3% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.53MShares$33.4 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.49MShares$32.5 Million0.0% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $572M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...